Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 10.25 378,550 08:00:00
Bid Price Offer Price High Price Low Price Open Price
10.00 10.50 10.25 10.25 10.25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 73.72 4.29 0.55 18.6 66
Last Trade Time Trade Type Trade Size Trade Price Currency
15:08:35 O 10,442 10.26 GBX

Allergy Therapeutics (AGY) Latest News

More Allergy Therapeutics News
Allergy Therapeutics Takeover Rumours

Allergy Therapeutics (AGY) Discussions and Chat

Allergy Therapeutics Forums and Chat

Date Time Title Posts
07/4/202011:55Allergy Therapeutics - AGY -3,788
14/7/201621:04Mike Mitchell Panmure Gordon who covers Allergy Therapeutics PLC (LON:AGY)1
16/12/201510:24Allergy Therapeutics-Transforming Allergy Treatment26
03/2/201213:58Ready to ROCKET?-
04/12/200512:00AGY - Allergy Therapeutics79

Add a New Thread

Allergy Therapeutics (AGY) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Allergy Therapeutics trades in real-time

Allergy Therapeutics (AGY) Top Chat Posts

Allergy Therapeutics Daily Update: Allergy Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 10.25p.
Allergy Therapeutics Plc has a 4 week average price of 7.38p and a 12 week average price of 7.38p.
The 1 year high share price is 16p while the 1 year low share price is currently 7.38p.
There are currently 644,117,768 shares in issue and the average daily traded volume is 439,967 shares. The market capitalisation of Allergy Therapeutics Plc is £66,022,071.22.
beccasan: Well I guess the current share price is a clear reflection of the mistrust we all have in the management. I think many things would need to change in order for investors to believe in the company again.
jimmyloser: Privately I was hoping that news of a large and credible distribution partnership in mainland China (as alluded to) would be announced at results in March and that the news would add impetus to the bombed out share price. Did I say mainland China? I think that someone must have smashed the mirror in the Worthing board room!
jpuff: Equally bemused by this depressed share price, but holding tight myself as I'm sure we'll get going up again soon.
eltorres70: How can anyone still believe in this company when all they do is fail and put smoke in people’s eyes, they’ve been doing this for the past 10 years and that’s a fact. And the regression of their share price is hard proof. Finncap is the same source that was suggesting 40p before people lost loads of money. Birch trial proved ineffectiveness of all their current injectible treatments. They have no viable plans for the future, competitors are already light years ahead. Only a naive speculator can still believe the tales they’re telling.
beccasan: I find it hard to firmly believe in AGY as much as you do Jimmy. After all the discussions on this board over the last few months, I am just not that confident anymore. We shall see how the birch trials turn out, but at the moment the market seems to be weak and this company is looking particularly weak against competitors, as it looks like all AGY projects are quite outdated while other similar companies are moving at a faster pace. We shall see once they start putting out news with results, but I currently wouldn't get my hopes too high up, and given the present share price I assume big investors are just as sceptic.
beccasan: I used to think like you but now I am not that sure anymore. This looks like a solid downwards trend, as share price is dropping at last 5% every day! In case bad news awaits in 2019 for the trials, things can get real bad real quick, I am personally very worried, very risky moment
mobox1: Current AGY website states these companies having major holdings: CFR International SPA & Associated Holding 240,584,571 37.82% Southern Fox Investments 127,238,783 22.69% Odey Assest Management 43,747,523 6.88% Black Rock Investment Management 30,368,413 4.79% Invesco 28,618,373 4.50& Black Rock still have someway to go if current % accurate & they want to offload everything. Annoying that they are selling at a time of little news and poor liquidity which knackers the share price. Can't have made them much profit.
gersemi: Today - IC Tip Update: Buy at 27p Megan Boxall The long await phase two clinical trial into Allergy Therapeutics’ (AGY) novel grass allergy vaccine has been successful. The trial managed to discover the appropriate dosage of the drug after a similar trial in 2015 failed to achieve any clinical significance. This latest update means Allergy can progress to its phase three study safe in the knowledge that patients are being given the appropriate dose. If the rest of Allergy’s product development goes according to plan, 2018 should be the last year that losses keep widening, according to Panmure Gordon. The grass vaccine, in particular, could be an enormous commercial success if it manages to pass its final trial thanks to the size of the allergy market, which is largely devoid of long-term treatments. IC View Even with the 9 per cent one-day share price hike which followed these results, Allergy’s share price is still down in the last 12 months. We don’t think that’s a fair reflection of the clinical progress that has been made in that time. Buy at 27p. Last IC View: Buy, 26p, 7 Mar 2018
jpuff: Why the collapse in the share price?
audigger: An encouraging start to the New Year..... Allergy Therapeutics plc 92.8% Potential Upside Indicated by finnCap Allergy Therapeutics plc with EPIC/TICKER LON:AGY had its stock rating noted as ‘Initiates/Starts’ with the recommendation being set at ‘BUY’ this morning by analysts at finnCap. Allergy Therapeutics plc are listed in the Health Care sector within AIM. finnCap have set their target price at 40 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 92.8% from the opening price of 20.75 GBX. Over the last 30 and 90 trading days the company share price has increased 0.67 points and increased 0.57 points respectively. Allergy Therapeutics plc LON:AGY has a 50 day moving average of 21.27 GBX and the 200 Day Moving Average price is recorded at GBX. The 1 year high share price is 30 GBX while the year low stock price is currently 17.25 GBX. There are currently 598,491,373 shares in issue with the average daily volume traded being 86,871. Market capitalisation for LON:AGY is £122,989,973 GBP.
Allergy Therapeutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Allergy Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200410 19:23:58